Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· July 21, 2026

Sagtec Global Limited Expands Strategic Partnership with Kinetic Seas to Launch Skilliks.AI Managed AI Memory Platform Across Southeast Asia

View original at globenewswire.com
Sagtec Global Limited Expands Strategic Partnership with Kinetic Seas to Launch Skilliks.AI Managed AI Memory Platform Across Southeast Asia KUALA LUMPUR, Malaysia, July 21, 2026 (GLOBE NEWSWIRE) -- Sagtec Global Limited (NASDAQ: SAGT) ("Sagtec" or the "Company"), a Nasdaq-listed technology solutions provider, today an…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • More than 80% of new databases provisioned on the Neon platform are now created automatically by AI agents rather than by human users.

    60% confidence
  • Memory is one of the most valuable assets an organization provides to its AI systems; MaluDB is designed to remain permanently open source, allowing organizations of all sizes to deploy enterprise-grade AI memory with governance and transparency, and the Sagtec partnership positions Kinetic Seas to support growing enterprise AI adoption across Southeast Asia.

    60% confidence
  • Southeast Asia's businesses are adopting AI rapidly, but many organizations remain focused on maintaining control over where their institutional knowledge resides; through this partnership, Sagtec can provide enterprise AI memory infrastructure built on open-source technology and supported by regional hosting capabilities, complementing its investment in sovereign AI infrastructure.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com